The article you requested is
Novel Antidepressant Strategies to Optimize Outcome
J Clin Psychiatry 2000;61(9):686-696
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
A resurgence of interest in the potent neurotransmitter norepinephrine (NE) and its role in depression has led investigators to realize that norepinephrinereuptake inhibitors (NRIs) may have a greater impact on drive, motivation, energy, and social functioning than selective serotonin reuptake inhibitors (SSRIs). This realization is the result of research on approaches to optimize the outcomes of patients with depression, whereby NE and serotonin have been compared with respect to their effects on antidepressant mechanisms of action and efficacy.